45 also proved that therapy with DPP4 inhibitors not only lowered the level of pro-inflammatory markers such as TNF-α, but it also increased the levels of anti-inflammatory cytokines what ultimately led to the reduction of inflammation in the blood serum of patients with diabetes. Here, DPP4 is linked to diabetes mellitus.